Evidence map›Paper›PMID 42315340›Full record

ArticleTobacco control2026

California's prohibition of flavoured tobacco sales and the tobacco industry's attempts to evade it.

Lauren Kass Lempert, Stella A Bialous, Pamela M Ling

Abstract readEditorial
In one paragraph

Article in Tobacco control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lauren Kass LempertCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA Lauren.Lempert@ucsf.edu.ORCID http://orcid.org/0000-0001-5421-0263
Stella A BialousCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-6471-5457
Pamela M LingCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA.ORCID http://orcid.org/0000-0001-6166-9347

Funding

Addressing disparities in tobacco-related diseases by understanding the tobacco industry strategiesR01CA268491 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STELLA AGUINAGA BIALOUS, Pamela May Ling · 2022 to 2026
$3.4M
NCI NIH HHS R01 CA268491
6 · The paper itself

Abstract

The tobacco industry has aggressively marketed menthol tobacco products because they are less harsh and more appealing to youth and other non-users. US law prohibits most flavours in tobacco products but exempts menthol from the ban. In 2020, California enacted a state law prohibiting retail sales of most flavoured tobacco products with 'characterising flavours', including menthol. Major tobacco companies vigorously opposed the law and sought its repeal. Despite spending millions of dollars to try to influence the legislature, ballot box and courts, the tobacco industry sought to evade the law by introducing so-called 'non-menthol' cigarettes. We describe those industry efforts and California's responses: California law was amended to redefine illegal flavoured products to include those that create a 'cooling sensation' to consumers and established an unflavoured tobacco list making it illegal for retailers to sell flavoured products not on the list. The California experience described in our paper provides a case study demonstrating some best practices that can be replicated by other US states and localities and other countries consistent with the WHO Framework Convention on Tobacco Control.

Indexed as

Advertising and PromotionGlobal healthPackaging and LabellingPublic policyTobacco industry

Identifiers

PMID42315340
PMCPMC13546624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.